MDCO - Agile Could Reach $10/Share After Twirla Approval
Agile Therapeutics (AGRX) is a now ~$230 million market capitalization biotech company that has just received approval from the FDA for its Twirla contraceptive patch. Based on my analysis of the situation and around past FDA precedent, I viewed this approval as highly likely as detailed in my Seeking Alpha posts here and here from when the stock could be bought below $3/share.
So, what's next for the company and its stock price? The future is bright.
Twirla's Commercial Prospects
Twirla is a once-a-week transdermal treatment with a combined hormonal approach that delivers a 30